Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Outlook on the Antisense & RNAi Therapeutics Global Market to 2030 - COVID-19 Growth and Change

Research and Markets Logo

News provided by

Research and Markets

Apr 09, 2021, 11:15 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, April 9, 2021 /PRNewswire/ -- The "Antisense & RNAi Therapeutics Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market.

The global antisense and RNAi therapeutics market reached a value of nearly $3,677.3 million in 2020, having increased at a compound annual growth rate (CAGR) of 38.2% since 2017. The market is expected to grow from $3,677.3 million in 2020 to $5,660.6 million in 2025 at a rate of 9.0%. The growth is mainly due to the growing demand for antisense and RNAi therapeutics due to COVID-19 which is expected to drive the demand for antisense and RNAi therapeutics. The market is expected to grow to $8,261.2 million in in 2030 at a CAGR of 7.9%. 

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market.

Description:

Where is the largest and fastest growing market for the antisense & RNAi therapeutics market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global antisense & RNAi therapeutics market opportunities and strategies to 2030 report answers all these questions and many more.

The report covers the following chapters

  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by technology, by route of administration and by indication.
  • Market Characteristics - The market characteristics section of the report defines and explains the antisense and RNAi therapeutics market. This chapter also defines and describes goods and related services covered in the report.
  • Trends and Strategies - This chapter describes the major trends shaping the global antisense and RNAi therapeutics market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact Of COVID-19 - This chapter discusses the impact of COVID-19 on the antisense and RNAi therapeutics market.
  • Global Market Size and Growth - This section contains the global historic (2017-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2017-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2017-2030) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region's market size (2020), historic (2017-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global antisense and RNAi therapeutics market, estimated market shares and company profiles for the leading players.
  • Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for antisense and RNAi therapeutics companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

The antisense & RNAi therapeutics market is highly concentrated, with a small number of large players. The top ten competitors in the market made up to 95.74% of the total market in 2019. Major players in the market include Biogen Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Moderna, Inc. and others.

The top opportunities in the antisense and RNAi therapeutics market segmented by technology will arise in the antisense RNA segment, which will gain $1,362.3 million of global annual sales by 2025. The top opportunities in the antisense and RNAi therapeutics market segmented by route of administration will arise in the intravenous injections segment, which will gain $962.6 million of global annual sales by 2025. The top opportunities in the antisense and RNAi therapeutics market segmented by indication will arise in the other indications segment, which will gain $ 1,056.1 million of global annual sales by 2025. The antisense and RNAi therapeutics' market size will gain the most in the USA at $737.1 million. Market-trend-based strategies for the antisense and RNAi therapeutics market includes focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, develop new and improved antisense and RNAi therapeutics, and collaborate with other companies for product innovation and to drive revenues. Player-adopted strategies in the antisense and RNAi therapeutics market include investing in expanding operations through innovative product launches, and in acquisitions and mergers to strengthen their service offerings.

To take advantage of the opportunities, the publisher recommends the antisense & RNAi therapeutics to focus on research and development for RNAi therapeutics to treat orphan diseases, expand product portfolios through collaborations, offer skimmed pricing, expand in emerging markets, promote their drugs through physicians and NGOs, increase visibility through websites and target people suffering from various diseases.

Key Topics Covered:

1. Antisense & RNAi Therapeutics Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1. Segmentation by Geography
6.2. Segmentation by Technology
6.3. Segmentation by Route of Administration
6.4. Segmentation by Indication

7. Antisense & RNAi Therapeutics Market Characteristics
7.1. Market Definition
7.2. Segmentation by Technology
7.2.1. RNA Interference
7.2.2. Antisense RNA
7.3. Segmentation by Route of Administration
7.3.1. Intravenous Injections
7.3.2. Intra-Dermal Injections
7.3.3. Other Delivery Methods
7.4. Segmentation by Indication
7.4.1. Oncology
7.4.2. Cardiovascular Diseases
7.4.3. Respiratory Disorders
7.4.4. Neurological Disorders
7.4.5. Infectious Diseases
7.4.6. Other Diseases

8. Antisense & RNAi Therapeutics Market Trends and Strategies
8.1. Demand for RNAi Therapeutics in the Treatment of Orphan Diseases
8.2. Revised FDA Regulations to Facilitate Drug Development
8.3. Growing Demand for Nanoparticles for Drug Delivery
8.4. Strategic Collaborations and Partnerships

9. COVID-19 Impact on the Antisense & RNAi Therapeutics Market
9.1. Using Antisense and RNAi Therapeutics in COVID-19 Vaccines
9.2. How Antisense and RNAi Companies are Tackling the Virus

10. Global Antisense & RNAi Therapeutics Market Size and Growth
10.1. Market Size
10.2. Historic Market Growth, 2017 - 2020, Value ($ Million)
10.2.1. Drivers of the Market 2017-2020
10.2.2. Restraints on the Market 2017-2020
10.3. Forecast Market Growth, 2020 - 2025, 2030F, Value ($ Million)
10.3.1. Drivers of the Market 2020-2025
10.3.2. Restraints on the Market 2020-2025

11. Global Antisense & RNAi Therapeutics Market Segmentation
11.1. Global Antisense & RNAi Therapeutics Market, Segmentation by Technology
11.2. Global Antisense & RNAi Therapeutics Market, Segmentation by Route of Administration
11.3. Global Antisense & RNAi Therapeutics Market, Segmentation by Indication

12. Antisense & RNAi Therapeutics Market, Regional and Country Analysis
12.1. Global Antisense & RNAi Therapeutics Market, by Region, Historic and Forecast, 2017 - 2020, 2025F, 2030F, Value ($ Million)
12.2. Global Antisense & RNAi Therapeutics Market, by Country, Historic and Forecast, 2017 - 2020, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Antisense & RNAi Therapeutics Market

14. Western Europe Antisense & RNAi Therapeutics Market

15. Eastern Europe Antisense & RNAi Therapeutics Market

16. North America Antisense & RNAi Therapeutics Market

17. South America Antisense & RNAi Therapeutics Market

18. Middle East Antisense & RNAi Therapeutics Market

19. Africa Antisense & RNAi Therapeutics Market

20. Global Antisense & RNAi Therapeutics Market Competitive Landscape
20.1. Company Profiles
20.2. Biogen Inc.
20.2.1. Company Overview
20.2.2. Products and Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Ionis Pharmaceuticals, Inc.
20.3.1. Company Overview
20.3.2. Products and Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Alnylam Pharmaceuticals, Inc.
20.4.1. Company Overview
20.4.2. Products and Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Arrowhead Pharmaceuticals, Inc.
20.5.1. Company Overview
20.5.2. Products and Services
20.5.3. Business Strategy
20.5.4. Financial Overview
20.6. Moderna, Inc.
20.6.1. Company Overview
20.6.2. Products and Services
20.6.3. Business Strategy
20.6.4. Financial Overview
20.7. Sanofi S.A.
20.7.1. Company Overview
20.7.2. Products and Services
20.7.3. Business Strategy
20.7.4. Financial overview
20.8. Dicerna Pharmaceuticals, Inc.
20.8.1. Company Overview
20.8.2. Products and Services
20.8.3. Business Strategy
20.8.4. Financial overview

21. Key Mergers and Acquisitions in the Antisense & RNAi Therapeutics Market
21.1. Secarna Pharmaceuticals Acquired Lipigon Pharmaceuticals
21.2. Astellas Pharma Acquired Gene Therapy Firm Audentes
21.3. Novartis International AG Acquired the Medicines Company
21.4. NeuBase Therapeutics Merged with Ohr Pharmaceutical
21.5. Novartis Acquired AveXis

22. Antisense & RNAi Therapeutics Market Opportunities and Strategies
22.1. Global Antisense & RNAi Therapeutics Market in 2025 - Countries Offering most New Opportunities
22.2. Global Antisense & RNAi Therapeutics Market in 2025 - Segments Offering most New Opportunities
22.3. Global Antisense & RNAi Therapeutics Market in 2025 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies

23. Antisense & RNAi Therapeutics Market, Conclusions and Recommendations

24. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/rab89e

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.